LONDON and PARIS, December 16, 2015: Global law firm Morgan Lewis represented private investment firm SK Capital Partners and minority co-owner Ion Beam Applications S.A. in the sale of IBA Molecular to private equity funds advised by CapVest Partners LP.
The transaction, announced on December 14, 2015, is expected to close at the end of the first quarter of 2016. SK Capital, a private investment firm, is focused on the specialty materials, chemicals and healthcare sectors. IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products.
The Morgan Lewis team was led by corporate partners Stephen Walters and Steven M. Cohen. Further team members included: partners Kevin Grant, Joerg Siegels, Richard Zarin, Izzet Sinan, Alexandre Bailly, Sabine Smith-Vidal; and associates Victoria Regis, Ryan Waggoner, Allison Soilihi, Sonia Namutebi, Tomislav Vrabec, Michael Engel, Lutz Krosien, Elizabeth Dennison, Irene De Beni, Noelia Martinez, Xavier Haranger, Charles Dauthier, and Peter Gumnior.
In July 2015, Morgan Lewis represented IBA Molecular in the sale of its US subsidiary IBA Molecular North America to Illinois Health and Science, and previously represented SK Capital Partners in its original investment in IBA Molecular.